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Abstract: 
Induced-pluripotent-stem cells (iPSCs) are derived from somatic cells and possess the 
ability to transform into a multitude of cell types. iPSCs are important for the clinical development 
of patient-specific cells for transplants and to create organoids for drug discovery research1–5. The 
first generation of iPSCs was accomplished by the Yamanaka method, which drives constitutive 
exogenous expression of four transcription factors (TFs; Oct4, Klf4, cMyc, Sox2) into the genome 
of somatic cells to induce pluripotenc6. Importantly, iPSCs generated via the Yamanaka method 
are reprogrammed inefficiently and the process is carcinogenic7,8. Recently, several small 
molecules that impact epigenetics have gained interest in cellular reprogramming due to their 
ability to activate the expression of endogenous reprogramming factors8–13. We have identified 
five small molecules (Mocetinostat, Droxinostat, Tacedinaline, Entinostat, and Azacytidine) that 
enhance the activation of a silenced Oct4 locus (a phenotypic indicator of cell reprogramming) in 
CiA:Oct4 mouse embryonic fibroblast (MEF) cells by recruiting the transcriptional activator VP16 
to that locus9,13–20. Here, we combine the transcription factor reprogramming method developed 
by Yamanaka with treatment using the identified small molecules to test whether they increase the 
efficiency of induction of pluripotency. The treatment was assessed for a period of 30 days post-
infection in an pulsating manner. Azacytidine and Mocetinostat increased the efficiency of cellular 
reprogramming from 0.05 percent, as observed in the Yamanaka method, to 27 and 31 percent, 
respectively, on average. Interestingly, Mocetinostat demonstrated an increased iPSC generation 
efficiency compared to 5-Azacytidine and our positive control valproic acid (VPA). This may 
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indicate it has applications in further iPSC generation studies including clinical and translational 
research. Furthermore, its success in increasing iPSC generation from MEFs to ESCs may indicate 
that it will work in other reprogramming methods such as neuronal transdifferentiation from 
somatic cells. 
 
Introduction: 
The development of induced pluripotent stem cells (iPSCs) was achieved by the Yamanaka 
method using four identified transcription factors: Oct4, Sox2, cMyc and Klf4 which, when 
exogenously expressed in mouse embryonic fibroblast (MEF) cells, led to cell reprogramming6. 
The obtained iPSCs have similar gene expression and markers when compared to embryonic stem 
cells (ESCs) and these cells are fully pluripotent. 
 ESCs are a type of stem cell 
capable of replicating for a long period of 
time in culture without differentiating. As 
their name suggests, ESCs are derived 
from embryos at the blastocyst stage and 
are capable of differentiating into a 
multitude of tissue types. Specifically, this 
quality, along with regeneration capabilities, are what make ESCs of special interest in 
regenerative medicine and research. ESCs are successfully used in current research therapies, 
however, their procurement is time consuming and carries along ethical ramifications21,22. 
 iPSC technology presents a possible replacement for ESCs, offering a virtually unlimited 
laboratory derived supply along with patient specificity (Fig. 1)1–5. However, several challenges 
Fig.1: Applications of iPSCs in regenerative medicine and research, 
adapted from Nishikawa et al.1 
A l e j o  | 3 
 
remain before iPSC technology can be widely used in clinical settings. Issues regarding the 
methods used to generate iPSCs have kept this technology away from useful applications both 
clinically and in research. The low efficiency of the original reprogramming process made the 
development of iPSCs time consuming7,8. MEFs had to be infected by each virus carrying one of 
the four reprogramming factors, four viral infections total, in order to undergo reprogramming. 
Thus, the efficiency of this process was rather low at 0.05%7. Safety concerns were also present in 
the Yamanaka method due to the random insertion of the four cassettes carrying the four 
Yamanaka TFs which could lead to mutagenesis and induce carcinogensis7. Another major safety 
concern is the overexpression of the four factors even after successful reprogramming, which could 
aid in the formation of tumorigenic cells since one of the four factors, cMyc, is a known 
oncogene23. 
The technology of iPSC generation has quickly advanced to address the downfalls of cell 
reprogramming. The use of non-integrating methods to deliver the four reprogramming factors 
such as episomal DNAs, mRNAs and Sendai virus circumvent safety issues and yield better 
efficiency than the original Yamanaka method9. The use of polycistronic vectors is another way to 
tackle both of these problems, inserting all four Yamanaka factors in one infection and thereby 
reducing the number of random insertions7. Somatic cells only need to be infected once in order 
to start expressing all four of the reprogramming factors, meaning that reprogramming is more 
likely to occur. Additionally, small molecules are being studied in their ability to aid the 
reprogramming process or even replace some/all the Yamanaka factors.  
The use of small molecules in reprogramming is of special interest because it could 
potentially substitute the use of viral constructs to exogenously express the four reprogramming 
factors. It is a safer, non-carcinogenic and more efficient option to cell reprogramming8,10–13,15,24. 
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Currently, the majority of small molecules used in iPSC generation are epigenetic modifiers such 
as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis)25. 
The use of small molecules in cell reprogramming is a promising approach due to the ease of small 
compounds to move across the cell membranes (size of up to 500 Da) as well as cost effectiveness 
and simplicity to administer as treatment16. The size of small molecules makes them easy to deliver 
to reprogramming cells and their treatment can be easily adjusted and standardized to maximize 
their efficiency. An example is 5-Azacytidine, a promising DNMTi which been shown to boost 
the efficiency of iPSC generation 3 fold as well as aid in direct reprogramming processes such as 
MEFs to adipocytes or bone cells, in which the intermediate pluripotent step is skipped25. 
Similarly, valproic acid (VPA), an HDACi, has shown an efficiency increase of 100 fold when 
used to aid iPSC generation. The generation of chemically induced pluripotent stem cells (CiPSCs) 
from mouse cells has been done using a cocktail of epigenetic modifiers as replacements for the 
original iPSC generating factors. However, this is a rather complicated procedure made up of three 
steps which requires the treatment of MEFs with different compound cocktails at each step. The 
mechanism behind CiPSCs needs to be further elucidated for this process to be viable and widely 
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Fig.2: Results of screen used to identify small molecules due to their ability to re-express a silenced Oct4 locus upon VP16 
recruitment. To the right are the chemical structures of the five top hit small molecules found through the screen.*** 
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used. Due to differences between murine iPSCs and human iPSCs, chemically induced iPSCs have 
not yet been developed from human cell lines9.  
The Hathaway laboratory has 
recently identified five small 
molecules capable of re-activating 
silenced Oct4 locus with 
simultaneous Gal4-VP16 recruitment 
in MEFs (Fig. 2). The screening 
was done using the chromatin in 
vivo assay (CiA), where two arrays of DNA binding sites (Gal4 and ZFHD1) are introduced 
upstream one of the Oct4 alleles in the MEFs and a nuclear GFP reporter gene replaces the first 
exon of the endogenous Oct4 (Fig. 3)14. Through chemically induced proximity ( CIP), this system 
is capable of reversibly tethering proteins of interest at the Oct4 locus. In this case VP16 was the 
protein of interest recruited to the locus along with each of the small molecules tested in the screen.  
From the five small molecules one is the DNMT inhibitor 5-Azacytidine, which 
specifically replaces cytosine in the DNA sequence and traps DNMTs in covalent bonds while 
signaling for degradation of those DNMTs. The other four small molecules are HDAC inhibitors: 
Entinostat, Mocetinostat, Droxinostat and Tacedinaline (Fig. 2). Of special interest to this project 
is Mocetinostat, an inhibitor of HDACs 1, 2, 3 and 11 which is currently in clinical trials for 
lymphoma and non-small cell lung cancer among others26. The exact mechanism of action is yet 
unknown but it is thought to be involved in apoptosis, cell cycle arrest, differentiation among 
others leading to tumor cell death by the inhibition of the mentioned HDACs. We focused much 
of our work on 5-Azacytidine because it was the most effective small molecule and only DNMTi 
Nuc 
EGFP GAL4 ZFHD1 
GFP 
Exon 1 
Fig.3: CiA Oct4 Mouse Model used for small molecule screen and iPSC 
generation.14 
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in the screen. It has also been shown in the literature to enhance cell reprogramming16,25. We also 
focused on Mocetinostat because it yielded the highest GFP activation relative to cell death as 
observed in the small molecule screen performed. Mocetinostat showed less toxicity in treated 
cells while maintaining GFP activation when compared to other hit compounds. Both 5-
Azacytidine and Mocetinostat showed greater than 20% activation of GFP upon retesting and dose 
curves performed on the five small molecules after the initial screen. 
The results of the screen indicate that the identified small molecules may be capable of 
increasing efficiency of iPSC generation because Oct4 is known to be a phenotypic indicator of 
cell reprogramming9,13,15–20. Thus we aim to determine whether the identified small molecules are 
capable of increasing the efficiency of iPSC generation from MEFs by driving reprogramming 
through the expression of endogenous Oct4. For this purpose, we use a GFP reporter linked to one 
allele of the endogenous Oct4 locus and quantify its expression as a marker for reprogramming 
(Fig.3)14. We also use alkaline phosphatase (AP) staining as a marker for induction of pluripotency 
because this enzyme is upregulated in embryonic stem cells and has been shown to be upregulated 
in iPSCs as well27. Our data suggests reprogramming activity is present within one month or 
earlier, on average, and variation in reprogramming yield has been observed between cells treated 
with the identified small molecules and the untreated controls, which is consistent with other 
published methods. The treatment of cells with 5-Azacytidine and Mocetinostat have shown an 
increase in GFP expression of 27 and 31 percent on average, respectively. Importantly 
Mocetinostat treated cells begin to express GFP earlier and experience lower cell death. 
 
Methods 
 
iPSC Generation: 
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The polycistronic plasmids OKSIM (24603), TetO-FUW-OSKM (20321) and FUW-
OSKM (20328) along with the tetracycline transactivator plasmid FUW-M2rtTA (20342) were 
obtained from Addgene with bacterial stabs. OKSIM and FUW-OSKM are polycistronic 
constructs containing all four of the Yamanaka factors under one promoter, both have puromycin 
resistance. TetO-FUW-OSKM is a Tet-on system dependent on doxycycline and the presence of 
the Tet-O protein, coded by FUW-M2rtTA, to polycistronically express the four Yamanaka 
factors, along with puromycin resistance. These were streaked on ampicillin plates and incubated 
at 37 °C for 12-14 hours. Colonies from each plate were picked and placed in 3 mL of lysogeny 
broth (LB) media with ampicillin for 8-12 hours while shaking at 250 rpm. Then, 200 microliters 
were taken from each liquid culture and used to inoculate a 200 mL culture in LB media with 
ampicillin, which was grown for another 12 hours at 37 °C while shaking at 250 rpm. The liquid 
culture was then centrifuged at 3300 rpm for 15 minutes, the supernatant was discarded, DNA was 
purified using the ZymoPureII Plasmid Maxiprep kit and its concentration measured using the 
Nanodrop 2000 spectrophotometer (Thermo Scientific). 
         The purified DNA was transfected individually into 293Tx cells using two lentiviral 
plasmids, psPAX2 containing the Gag and Pol genes for packaging and pMD2.G containing the 
VSVG gene for the viral envelope formation. Transfected cells were grown for 48 hours post-
transfection and incubated at 37° Celsius. Supernatant from transfected cells was collected and 
filtered into ultracentrifuge tubes for virus isolation. The supernatant was ultracentrifuged for 2.5 
hours at 20,000 rpm and 4 degrees Celsius. The virus was then re-suspended in phosphate buffered 
saline (PBS) (150 microliters) and incubated at 10 degrees Celsius while spinning for 20-30 
minutes. Polybrene media (2.2 μL of polybrene per 1 mL of MEF media) was prepared and added 
to MEFs (0.5 mL per well) before adding 60 μL of the concentrated virus. Following infection, the 
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cells are centrifuged at 1000 XG for 25 minutes and incubated at 37 °C. After 48 hours, infected 
cells are split and changed into ESC conditions, using ESC media containing leukemia inhibitory 
factor (LIF) as well as gelatin coated plates. Doxycycline was added at this time as well for Tet-
on system (20322). The cells were then selected using puromycin at concentrations of 0.313 to 
0.625 μL per 10 mL of media. Cells were split every 2 days at 5-10% depending on confluence. 
Small Molecule Stamp Plates: 
Small molecules were added to master plate at 1000 times the desired treatment 
concentration from stocks. For 5-Azacytidine, 2.5 mM, for Mocetinostat 0.156 mM and for VPA 
2 M. Dimethyl sulfoxide (DMSO) was added in the same volume to wells for negative controls. 
Doxycycline was added from stock of 1 mg/mL to corresponding wells for each small molecule 
for simultaneous addition to reprogramming cells. The master plate was divided into 40 stamp 
plates each with 1 microliter from each well using the Mosquito HTS (TTPLabtech). Plates were 
then labeled and stored at -20 degrees Celsius until used. 
Small Molecule Treatment: 
When infected cells started showing GFP+ colonies, they were split and small molecule 
treatment was started (on average 1-week post-infection). Cells were treated with 2.5 μM 5-
Azacytidine and with 0.156 μM Mocetinostat. These concentrations were identified to yield the 
highest GFP expression without causing cell death in a dose curve experiment as part of the small 
molecule screen. We also used VPA as a positive control for iPSC generation at concentration of 
2.0 mM due to its ability to increase iPSC generation by 100 fold as reported on the literature25. 
All small molecules were added from the stamp plates described above by re-suspending in 100 
μL of ESC media and adding directly to wells. Cells were treated in triplicates under small 
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molecules and small molecule plus doxycycline also including a negative control treated with 
DMSO. Small molecules were added in a pulsating manner, every two days post-infection. 
Imaging: 
Infected cells were imaged using the GE IN CELL Analyzer 2200 high throughput 
microscope every two days during the first week post-infection and after SM treatment every time 
before splitting. Cells were observed under brightfield and FITC channels and pictures were taken 
under the same conditions and following a standard protocol for each of the iPSC generations. 
Images were analyzed for GFP expression using GE IN CELL Developer.   
Flow Cytometry: 
On days 5-7 post-infection cells were analyzed using the Intellicyt iQue Screener PLUS 
flow cytometer as they were passaged. Between 5-10% of the cells were taken for flow cytometry 
analysis and re-suspended in 50 microliters of flow cytometry (FACS) buffer. Cells were gated for 
live cells, singlets and GFP+ cells were specified using a gate on GFP versus RFP plot. The same 
standard protocol was used for data acquisition for all of the iPSC generations. Flow cytometry 
data was later analyzed using FlowJo. 
Alkaline Phosphatase Stain: 
An AP staining kit (Stemgent) was used to identify induction of pluripotency after 25-30 
days post-infection. Procedure was followed according to the manufacturer protocol. Cells were 
imaged using the InCell Analyzer in the following channels: brightfield, FITC, Cy3 and Cy5. 
Pictures were analyzed using Developer to look for overall co-localization of AP stains and GFP+. 
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Results: 
Determining most Effective form of Treatment: 
To identify the most 
effective time series for the 
small molecules treatments 
during iPSC generation we 
first treated the cells infected 
with the TetO-FUW-OSKM + 
FUW-M2rtTA and FUW-
OSKM constructs for one 
week (starting at 48 hours 
post infection). The small 
molecules used were 5-
Azacytidine and Mocetinostat at concentrations of 2.5 μM and 0.02 μM, respectively. Cell imaging 
showed higher GFP expression in cells two days after the first treatment with 5-Azacytidine and 
Mocetinostat (data not shown). However, the effect of the small molecules decreased after the 
treatment stopped, leading to diminished GFP expression. As a result, we treated the cells in a 
pulsating manner for the second iPSC generation, adding the small molecules in the same 
concentrations as before but every other week to maintain the effects of the epigenetic modifiers. 
This change in treatment led to enhanced maintenance of GFP expression in the treated wells at 
0.5-1 percent higher when compared to the first iPSC generation cells which were treated for only 
Fig. 4: Number of GFP+ cells obtained using flow cytometry for one time, pulsating and 
continuous treatments of 5-Azacytidine and Mocetinostat on reprogramming MEFs. 
Observed for MEFs infected with TetO-FUW-OSKM along with the FUW-M2rtTA 
transactivator.  
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one week (Fig. 4). Although GFP expression decreased after the first week of treatment it was 
maintained at 2 percent for TetO-FUW-OSKM infected cells and 0.6 percent in FUW-OSKM 
infected cells, on average, above the negative controls. We have also tested the cells under 
continuous and pulsating treatment with small molecules. GFP expression has been maintained 
higher in cells under the pulsating treatment with small molecules and less cell death is observed 
as well (Fig. 4) Thus, we have identified that treating the infected MEFs in a pulsating manner 
with the small molecules yields higher efficiency in the generation of iPSCs (Fig.4). 
AP staining shows iPSC colonies presence: 
To characterize the infected MEFs expressing GFP into growing iPSCs we used alkaline 
phosphatase (AP) staining, since AP is an overexpressed enzyme in ESCs27. We observed strong, 
marked stains in cells which were treated and kept under ESC conditions for 20-30 days post-
infection. The stains were concentrated in colony-like formations, indicating presence of iPSCs6. 
Control 
Aza 
Moc 
Aza 
Moc 
A           +/- SVT CiA Oct4 MEFs B         -/- CiA Oct4 MEFs 
AP Stain AP Stain GFP Phase Phase 
Fig. 5: Alkaline Phosphatase staining on reprogramming MEFs. Panel A: Imaging of AP stained reprogramming MEFs using different 
channels to visualize presence of stain and co-localization with GFP expression in CiA Oct4 MEFs which have a GFP reporter in one Oct4 
allele. Panel B: Imaging of CiA Oct4 primary MEFs without a GFP reporter in one Oct4 allele. 
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In some instances, the AP stains corresponded with GFP expressing cells but this was not 
uniformly observed (Fig.5). Overall, wells with the highest AP staining also showed higher GFP 
expression, even if these were not always co-localized. The method was also tried on unmodified 
MEFs which did not have a GFP on one of the endogenous Oct4 alleles. The results showed highly 
specific, strong and circular stains indicative of iPSC generation (Fig. 5). The staining was more 
marked in non Oct4/GFP MEFs. 
Mocetinostat is most Effective in iPSC generation: 
We have also used another HDAC inhibitor, valproic acid (VPA), as a positive control due 
to its reported efficacy in cell reprogramming25. Cells treated with Mocetinostat and 5-Azacytidine 
Fig. 6: Flow cytometry data of GFP expression in reprogramming SVT CiA Oct 4 MEFs under different small molecule treatments at 
two time points during the reprogramming process. To the right are pictures of the reprogramming MEFs under different small molecules 
treatments corresponding to each of the two time points shown in the graphs. Flow cytometry was not performed for Aza+Dox treated 
cells at the 25 day timepoint due to significant cell death. Wells were allowed to grow until confluent enough to split and perform flow 
cytometry analysis. This was done at 33 days post infection, and Aza+Dox cells had a GFP+ percentage of 27.6. Picture to the right of 
25 day timepoint graph for Aza+Dox is representative of that later timepoint as well. 
Control 
Control 
VPA 
VPA 
Aza 
Aza 
Moc 
Moc 
Control VPA 
Aza Moc 
Control VPA 
Aza Moc 
Phase GFP Phase GFP 
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had GFP percentages of 1.18 and 1.48, respectively, and VPA of 11.8 percent. Importantly, an 
adjustment to the Mocetinostat treatment concentration from 0.020 μM to 0.156 μM has 
maximized the percentage of GFP expressing cells. This experiment has shown an increased GFP 
expression in cells infected with the TetO-FUW-OSKM + FUW-M2rtTA constructs. Upon flow 
cytometry analysis, reprogramming cells treated with 5-Azacytidine and Mocetinostat in a 
pulsating manner show a percentage GFP expression of 27 and 31 percent on average, respectively, 
while VPA shows an average of 20 percent (Fig. 6). However, the level of cell death is significantly 
lower in Mocetinostat treated cells (Fig. 6).   
Discussion and Conclusion 
The differences observed in overall GFP expression between cells treated for one-week 
post-infection, treated in a pulsating manner throughout one-month post infection or a continuous 
manner suggest that a periodical treatment with the small molecules increases the efficiency of 
CiA Oct4 +/- SVT MEFs 
Infected with TetO-
FUW-OSKM and FUW-
M2rtTA plasmids. 
Under ESC and 
doxycycline conditions, 
 
Pulsating Addition of SM 
AP staining 
Found presence of 
iPSC colonies 
increasingly in SM 
treated wells 
within 20-30 days 
of reprogramming 
and treatment 
Flow Cytometry Quantification of GFP+ cells 
Found that 
Mocetinostat 
treated wells 
have higher GFP+ 
percentages 
earlier in 
reprogramming 
process  Future Directions: 
• Viability Assays 
• Test other SMs from screen 
• Check for synergy among SMs 
• Check for other iPSC markers 
• Apply to other reprogramming 
processes 
Fig. 7: Summary of findings and conclusions from the reported experiments. Starting with finding that the pulsating addition of the 
SMs to the reprogramming MEFs is the most efficient way to increase the efficiency of the reprogramming process while minimizing 
damage to cells. Also that AP staining towards 20-30 days post-infection shows presence of iPSC colonies especially in the SM 
treated wells. Furthermore, that quantification of GFP presence in wells using flow cytometry shows that, of our experimental and 
control conditions, Mocetinostat has the highest GFP expression percentage earlier in the reprogramming process and that this is 
maintained throughout the reprogramming process. Finally, some future directions for this experiment are shown as well.  
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GFP expression in reprogramming MEFs (Fig. 7). The continuous small molecules treatment 
lowers GFP activation compared to the pulsating treatment, and the one week treated cells lose 
GFP activation progressively. However, pulsating treatment allows for the maintenance of GFP 
expression in small molecule treated wells over time.  We hypothesize that the effects of 
methylation inhibition and de-acetylation inhibition caused by the small molecules is better 
maintained through the pulsating addition of the small molecules. It is likely that stopping 
treatment after 1 week leads to the reversal of the small molecules’ effects over time, leading to a 
decrease in endogenous Oct4 expression and thus in GFP expression. Moreover, the continuous 
activation of small molecules may contribute to cell death and prevent the overall reprogramming 
process. 
The staining of infected MEFs with AP stain between 20-30 days post-infection yielded 
positive and strong AP staining suggesting that the MEFs are reprogramming and becoming more 
ESC-like (Fig. 7). Primary MEFs specially showed very marked AP positive colonies, which are 
consistent with the morphology changes observed during reprogramming and characteristic of 
ESCs. Interestingly, AP staining in the Oct4-GFP MEFs did not always show coincidence of AP 
stain marks and GFP expressing cells. Although staining was strong and comparable to that 
observed in primary MEFs, it was expected to coincide with GFP positive cells since these cells 
are expressing endogenous Oct4 and driving reprogramming. Correlation was observed between 
AP staining and GFP expression, but it was not exclusive to GFP expressing cells. These results 
suggest that even cells which are not expressing GFP could be undergoing reprogramming since 
we do not account for the three other iPSC generating factors in our assay. The literature also 
suggests that GFP expression representing endogenous Oct4 expression is an indicator of increased 
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reprogramming efficiency but not a marker for iPSC generation, not all GFP expressing cells will 
successfully reprogram6,12,24. 
Importantly, treatment with small molecules 5-Azacytidine and Mocetinostat helped 
activate the Oct4 locus and drive reprogramming compared to non-treated reprogramming cells. 
The reprogramming efficiency, based on quantification of GFP expressing cells using flow 
cytometry, of 5-Azacytidine and Mocetinostat treated wells was of 1.48 and 1.18, respectively, in 
early experiments. This is, as expected, lower than the efficiency increase caused by treatment 
with VPA which leads to 11.8% iPSC generation12. However, the dose concentrations for VPA to 
obtain such a result were much greater than that of Mocetinostat and 5-Azacytidine, suggesting 
that these small molecules may have future applications due to higher potency for induction of 
pluripotency. Interestingly, cells treated with Mocetinostat showed cell death of 11.8% whereas 
those treated with 5-Azacytidine and VPA have cell death of 50%. Similarly, in the triplicate 
experiments cells treated with Mocetinostat show a higher GFP expression while having 
significantly less cell death than other treated wells. The percentage of GFP expressing cells is 
much higher in the triplicate experiments, likely due to the use of more concentrated lentiviral 
packaging plasmids during transfection as a result of better DNA isolation assays. In these later 
experiments Mocetinostat shows to be fast acting, with a GFP activation of 31 percent on average 
within the first 20 days of treatment. VPA and 5-Azacytidine are slower acting and reached GFP 
percentages of 20 and 27 percent, respectively, later in the reprogramming process. Although the 
change in GFP expression between these two sets of experiments is significant, all three treatment 
conditions increased with the use of more concentrated virus to deliver the Yamanaka TFs. 
Furthermore, the overall increase in GFP expression for treated wells remains higher than the 
negative controls (untreated wells), suggesting that the observed increase in GFP is a result of 
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more concentrated viral constructs for infection along with the SM treatment. This is a consistent 
observation in the later experiments which suggests that Mocetinostat may be of special interest 
due to its high potency and low toxicity in cells during cellular reprogramming (Fig. 7).  
We have found that treatment of reprogramming MEFs in a pulsating manner is more 
efficient in GFP maintenance than either one time or continuous treatments. Upon AP staining, we 
observed that although there is correlation between AP stain and GFP expression, the stain is not 
exclusive to GFP expressing cells. This suggests cells not expressing GFP might also be 
undergoing reprogramming and corroborates GFP expression suggests reprogramming but is not 
a direct marker for it. Finally, pulsating treatment with 5-Azacytidine and Mocetinostat leads to 
increase in reprogramming efficiency over untreated controls while showing lower cell death, 
especially for Mocetinostat. Importantly, Mocetinostat is a novel small molecule which shows 
potential in increasing the efficiency of cellular reprogramming at much lower doses than 
traditionally used small molecules liked VPA and 5-Azacytidine. 
Currently, we are using cell viability assays to corroborate that Mocetinostat not only 
shows lower cell death but may also maintain cell viability during the reprogramming process. 
Future steps are still needed to examine the other three identified HDACis in the process of iPSC 
generation and to test combinations of the top five hits to check whether the synergism observed 
in the small molecule screen is translatable. Furthermore, we will test these small molecules in 
other reprogramming methods such as direct neuron transdifferentiation from MEFs. Ultimately, 
the goal is to apply this work to the induction of pluripotency from human somatic cells and make 
iPSC generation more readily usable for clinical and other research applications. 
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